Etienne B.
- Country
- France
- Department
- NA
Research Overview
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- Phase II Evaluation of Vemurafenib Monotherapy in Patients with Metastatic or Unresectable Locally Advanced Malignancies Harboring BRAF Genomic Alterations
- Phase II Trial of Durvalumab, Olaparib, and Fulvestrant in ER-Positive, HER2-Negative Metastatic Breast Cancer with BRCA or HRR Gene Alterations
Data & Insights
Has run more than one trial at 146 of 426 partner sites.
Specializations
Breast Cancer Treatment Innovation
This investigator specializes in advanced therapeutic approaches for hormone receptor-positive breast cancer, with particular emphasis on endocrine therapy combinations and novel targeted treatments.
- Hormone Receptor-Positive Disease Management
- HER2-Negative Breast Cancer Therapeutics
- Advanced Metastatic Treatment Strategies
Their research encompasses both early-stage and metastatic breast cancer treatments.
Precision Medicine Applications
The investigator focuses on targeted therapeutic approaches utilizing specific genetic and molecular markers, including BRCA mutations and genomic alterations.
- Molecular-Guided Treatment Selection
- Biomarker-Driven Therapy
- Genetic Mutation Analysis
Their work integrates molecular diagnostics with personalized treatment strategies.
Novel Therapeutic Combinations
Research initiatives explore innovative drug combinations including CDK4/6 inhibitors, PARP inhibitors, and targeted antibody treatments.
- Combination Therapy Development
- Drug Resistance Management
- Treatment Optimization Strategies
The focus includes developing effective therapeutic combinations for complex disease presentations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.